4D Molecular Therapeutics, Inc. reported that as of November 6, 2025, it had approximately $372.2 million in cash and revealed positive interim data from its Phase 1/2 PRISM trial for wet AMD, showing significant treatment benefits with a 94% reduction in supplemental injections in certain cohorts.